Curis to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
Wednesday March 30, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 30, 2005--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced that the Company will be presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Tuesday, April 5, at the Millennium Broadway Hotel in New York City.
Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 10:30 a.m. EST. There will be an audio webcast of the presentation at:
veracast.com
It will be archived approximately 3 hours after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under partnership with Genentech, which also includes a co-development collaboration between Curis and Genentech for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech, a subsidiary of Johnson & Johnson), neurological disorders (partnered with Wyeth Pharmaceuticals), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
